Fourth quarter saw a slew of US approvals, including those for three new therapies for multiple myeloma, two for melanoma (including the first oncolytic virus) and the first biosimilar. US Food and Drug Administration (FDA) breakthrough designations included an adoptive T cell therapy and a live microbiome treatment. Muscular dystrophy patients will have to wait until late February for any good news, as the FDA shot down a highly anticipated antisense therapy in January.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline Q4 2015. Nat Biotechnol 34, 128 (2016). https://doi.org/10.1038/nbt.3484
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3484
This article is cited by
-
The landscape of new drugs in lymphoma
Nature Reviews Clinical Oncology (2017)
